文献速递糖尿病肥胖与代谢综合征

替尔泊肽治疗2型糖尿病:系统综述与Meta分析

Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis.
PubMed 文献 · Diabetologia · 2022-05-17

该系统综述与Meta分析检索截至2021年10月27日的随机对照试验,纳入7项试验共6609例2型糖尿病成人患者。结果显示,替尔泊肽5、10、15 mg在降低HbA1c和体重方面呈剂量依赖性优于安慰剂、GLP-1受体激动剂和基础胰岛素,不增加低血糖风险,但胃肠道不良事件增多。

要点

  • 替尔泊肽降低HbA1c呈剂量依赖性,优于安慰剂、GLP-1受体激动剂和基础胰岛素。
  • 替尔泊肽减重优于GLP-1受体激动剂,5 mg至15 mg减重幅度递增。
  • 替尔泊肽与安慰剂相比低血糖发生率相似,与基础胰岛素相比更低。

核心结论

  • 与安慰剂、GLP-1受体激动剂和基础胰岛素相比,替尔泊肽在血糖疗效和减重方面呈剂量依赖性优势。
  • 替尔泊肽未增加低血糖的比值,但与胃肠道不良事件发生率升高相关。

研究设计与样本

  • 系统综述与Meta分析,检索PubMed、Embase、Cochrane和ClinicalTrials.gov至2021年10月27日。
  • 纳入至少12周的随机对照试验,比较每周一次替尔泊肽5、10或15 mg与安慰剂或其他降糖药,受试者为2型糖尿病成人。
  • 共纳入7项试验、6609例参与者,主要结局为HbA1c自基线的变化。
  • 使用Cochrane随机试验偏倚风险工具第2版评估主要结局的偏倚风险。
  • PROSPERO注册号CRD42021283449。

主要发现

  • 三个替尔泊肽剂量对比所有对照均显示降低HbA1c的剂量依赖性优势:对比安慰剂的平均差异为-17.71 mmol/mol(-1.62%)至-22.35 mmol/mol(-2.06%)。
  • 对比GLP-1受体激动剂的HbA1c平均差异为-3.22 mmol/mol(-0.29%)至-10.06 mmol/mol(-0.92%)。
  • 对比基础胰岛素方案的HbA1c平均差异为-7.66 mmol/mol(-0.70%)至-12.02 mmol/mol(-1.09%)。
  • 对比GLP-1受体激动剂的体重降低为替尔泊肽5 mg的1.68 kg至替尔泊肽15 mg的7.16 kg。
  • 替尔泊肽与安慰剂相比恶心更频繁,尤其替尔泊肽15 mg(OR 5.60 [95%CI 3.12, 10.06]),伴呕吐(OR 5.50 [95%CI 2.40, 12.59])和腹泻(OR 3.31 [95%CI 1.40, 7.85])发生率更高。

关键数值与推荐

  • 替尔泊肽与安慰剂相比低血糖发生率相似,与基础胰岛素相比更低。
  • 替尔泊肽与GLP-1受体激动剂之间胃肠道事件比值相似,但替尔泊肽10 mg的腹泻除外(OR 1.51 [95%CI 1.07, 2.15])。
  • 替尔泊肽15 mg因不良事件停药率高于对照,不论对照类型;所有替尔泊肽剂量在严重不良事件和死亡率方面均安全。

局限性

  • Meta分析中HbA1c变化和体重变化存在统计学异质性。
  • 仅对主要结局评估了偏倚风险。
  • 研究结果主要适用于超重或肥胖且已接受二甲双胍为基础治疗的个体。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Tirzepatide is a novel dual glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 receptor agonist (GLP-1 RA) currently under review for marketing approval. Individual trials have assessed the clinical profile of tirzepatide vs different comparators. We conducted a systematic review and meta-analysis to assess the efficacy and safety of tirzepatide for type 2 diabetes. METHODS: We searched PubMed, Embase, Cochrane and ClinicalTrials.gov up until 27 October 2021 for randomised controlled trials with a duration of at least 12 weeks that compared once-weekly tirzepatide 5, 10 or 15 mg with placebo or other glucose-lowering drugs in adults with type 2 diabetes irrespective of their background glucose-lowering treatment. The primary outcome was change in HbA1c from baseline. Secondary efficacy outcomes included change in body weight, proportion of individuals reaching the HbA1c target of <53 mmol/mol (<7.0%), ≤48 mmol/mol (≤6.5%) or <39 mmol/mol (<5.7%), and proportion of individuals with body weight loss of at least 5%, 10% or 15%. Safety outcomes included hypoglycaemia, gastrointestinal adverse events, treatment discontinuation due to adverse events, serious adverse events, and mortality. We used version 2 of the Cochrane risk-of-bias tool for randomised trials to assess risk of bias for the primary outcome. RESULTS: Seven trials (6609 participants) were included. A dose-dependent superiority in lowering HbA1c was evident with all three tirzepatide doses vs all comparators, with mean differences ranging from -17.71 mmol/mol (-1.62%) to -22.35 mmol/mol (-2.06%) vs placebo, -3.22 mmol/mol (-0.29%) to -10.06 mmol/mol (-0.92%) vs GLP-1 RAs, and -7.66 mmol/mol (-0.70%) to -12.02 mmol/mol (-1.09%) vs basal insulin regimens. Tirzepatide was more efficacious in reducing body weight; reductions vs GLP-1 RAs ranged from 1.68 kg with tirzepatide 5 mg to 7.16 kg with tirzepatide 15 mg. Incidence of hypoglycaemia with tirzepatide was similar vs placebo and lower vs basal insulin. Nausea was more frequent with tirzepatide vs placebo, especially with tirzepatide 15 mg (OR 5.60 [95% CI 3.12, 10.06]), associated with higher incidence of vomiting (OR 5.50 [95% CI 2.40, 12.59]) and diarrhoea (OR 3.31 [95% CI 1.40, 7.85]). Odds of gastrointestinal events were similar between tirzepatide and GLP-1 RAs, except for diarrhoea with tirzepatide 10 mg (OR 1.51 [95% CI 1.07, 2.15]). Tirzepatide 15 mg led to higher discontinuation rate of study medication due to adverse events regardless of comparator, while all tirzepatide doses were safe in terms of serious adverse events and mortality. CONCLUSIONS/INTERPRETATION: A dose-dependent superiority on glycaemic efficacy and body weight reduction was evident with tirzepatide vs placebo, GLP-1 RAs and basal insulin. Tirzepatide did not increase the odds of hypoglycaemia but was associated with increased incidence of gastrointestinal adverse events. Study limitations include presence of statistical heterogeneity in the meta-analyses for change in HbA1c and body weight, assessment of risk of bias solely for the primary outcome, and generalisation of findings mainly to individuals who are overweight or obese and already on metformin-based background therapy. PROSPERO registration no. CRD42021283449.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Karagiannis T, Avgerinos I, Liakos A, et al. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia. 2022. PMID: 35579691. doi:10.1007/s00125-022-05715-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。